JP2008543758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008543758A5 JP2008543758A5 JP2008515878A JP2008515878A JP2008543758A5 JP 2008543758 A5 JP2008543758 A5 JP 2008543758A5 JP 2008515878 A JP2008515878 A JP 2008515878A JP 2008515878 A JP2008515878 A JP 2008515878A JP 2008543758 A5 JP2008543758 A5 JP 2008543758A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tanaproget
- ethinyl estradiol
- pharmaceutically acceptable
- daily dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 48
- PYVFWTPEBMRKSR-UHFFFAOYSA-N tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 claims 17
- 229950001471 tanaproget Drugs 0.000 claims 17
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims 14
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 14
- 229960002568 ethinylestradiol Drugs 0.000 claims 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 14
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 9
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 7
- 229960004977 anhydrous lactose Drugs 0.000 claims 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 7
- 235000019359 magnesium stearate Nutrition 0.000 claims 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 3
- 238000002657 hormone replacement therapy Methods 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 229940057948 magnesium stearate Drugs 0.000 claims 2
- 230000000708 anti-progestin effect Effects 0.000 claims 1
- 239000003418 antiprogestin Substances 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940068196 placebo Drugs 0.000 claims 1
- 239000000902 placebo Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68880605P | 2005-06-09 | 2005-06-09 | |
| US60/688,806 | 2005-06-09 | ||
| PCT/US2006/022150 WO2006135638A2 (en) | 2005-06-09 | 2006-06-07 | Tanaproget compositions containing ethinyl estradiol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008543758A JP2008543758A (ja) | 2008-12-04 |
| JP2008543758A5 true JP2008543758A5 (enExample) | 2009-07-23 |
| JP5339903B2 JP5339903B2 (ja) | 2013-11-13 |
Family
ID=37432377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008515878A Expired - Fee Related JP5339903B2 (ja) | 2005-06-09 | 2006-06-07 | エチニルエストラジオールを含むタナプロゲット組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20060280800A1 (enExample) |
| EP (1) | EP1893217A2 (enExample) |
| JP (1) | JP5339903B2 (enExample) |
| CN (2) | CN103989687A (enExample) |
| AR (1) | AR057060A1 (enExample) |
| AU (1) | AU2006258048A1 (enExample) |
| BR (1) | BRPI0611250A2 (enExample) |
| CA (1) | CA2610767C (enExample) |
| HN (1) | HN2006020928A (enExample) |
| MX (1) | MX2007015571A (enExample) |
| PE (1) | PE20070001A1 (enExample) |
| TW (1) | TW200716137A (enExample) |
| WO (1) | WO2006135638A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01011287A (es) * | 1999-05-04 | 2003-07-14 | American Home Prod | Derivados de ciclotiocarbamato como moduladores de receptor de progesterona. |
| DE602006007453D1 (de) | 2005-04-28 | 2009-08-06 | Wyeth Corp | Zusammensetzungen mit mikronisiertem tanaproget |
| US20060246128A1 (en) * | 2005-04-28 | 2006-11-02 | Wyeth | Micronized tanaproget and compositions containing same |
| AR056328A1 (es) * | 2005-04-28 | 2007-10-03 | Wyeth Corp | TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN |
| MX2007013469A (es) * | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| CN103989687A (zh) | 2005-06-09 | 2014-08-20 | 惠氏公司 | 含有炔雌醇的tanaproget组合物 |
| EA201070715A1 (ru) | 2007-12-20 | 2011-02-28 | Тева Вимен'С Хелс, Инк. | Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции |
| EP3763374A1 (en) * | 2011-10-17 | 2021-01-13 | Lexicon Pharmaceuticals, Inc. | Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20140006315A1 (en) * | 2012-07-02 | 2014-01-02 | Stèphane Etheve | Method of marketing oregano capsules containing thymoquinone |
| US9326997B2 (en) | 2012-09-24 | 2016-05-03 | Ahlam E. Elakkad | Composition and method for treation Oligoovulation, Oligomenorrhea and Amenorrhea |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014159377A1 (en) * | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
| MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01011287A (es) * | 1999-05-04 | 2003-07-14 | American Home Prod | Derivados de ciclotiocarbamato como moduladores de receptor de progesterona. |
| US6423699B1 (en) * | 1999-05-04 | 2002-07-23 | American Home Products Corporation | Combination therapies using benzimidazolones |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| BR0312024A (pt) * | 2002-06-25 | 2005-03-22 | Wyeth Corp | Uso de derivados de ciclotiocarbamato no tratamento de condições relacionadas com hormÈnios |
| AR040644A1 (es) | 2002-06-25 | 2005-04-13 | Wyeth Corp | Un moduladores del receptor de progesterona benzoxazina-2-tiona, una composicion farmaceutica, uso del compuesto para preparar un dedicamento para tratar una enfermedad neoplasica-hormona-dependiente y el uso de un compuesto benzoxazina-2-tiona, benzoxazina-2-ilideno cianamida o benzoxazina-2-iliden |
| CN104208067A (zh) * | 2004-07-07 | 2014-12-17 | 惠氏公司 | 周期性黄体酮方案及试剂盒 |
| SI1778710T1 (sl) * | 2004-08-13 | 2012-05-31 | Wyeth Llc | Derivati tanaprogeta metaboliti in njihove uporabe |
| EP1874743B1 (en) | 2005-04-28 | 2013-07-17 | Wyeth LLC | Purified form of tanaproget |
| DE602006007453D1 (de) | 2005-04-28 | 2009-08-06 | Wyeth Corp | Zusammensetzungen mit mikronisiertem tanaproget |
| MX2007013469A (es) | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| AR056328A1 (es) | 2005-04-28 | 2007-10-03 | Wyeth Corp | TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN |
| US20060246128A1 (en) | 2005-04-28 | 2006-11-02 | Wyeth | Micronized tanaproget and compositions containing same |
| CN103989687A (zh) | 2005-06-09 | 2014-08-20 | 惠氏公司 | 含有炔雌醇的tanaproget组合物 |
-
2006
- 2006-06-07 CN CN201410160290.6A patent/CN103989687A/zh active Pending
- 2006-06-07 JP JP2008515878A patent/JP5339903B2/ja not_active Expired - Fee Related
- 2006-06-07 EP EP06772444A patent/EP1893217A2/en not_active Ceased
- 2006-06-07 CN CNA200680020195XA patent/CN101193639A/zh active Pending
- 2006-06-07 HN HN2006020928A patent/HN2006020928A/es unknown
- 2006-06-07 TW TW095120116A patent/TW200716137A/zh unknown
- 2006-06-07 WO PCT/US2006/022150 patent/WO2006135638A2/en not_active Ceased
- 2006-06-07 CA CA2610767A patent/CA2610767C/en not_active Expired - Fee Related
- 2006-06-07 BR BRPI0611250-1A patent/BRPI0611250A2/pt not_active IP Right Cessation
- 2006-06-07 MX MX2007015571A patent/MX2007015571A/es unknown
- 2006-06-07 PE PE2006000630A patent/PE20070001A1/es not_active Application Discontinuation
- 2006-06-07 AU AU2006258048A patent/AU2006258048A1/en not_active Abandoned
- 2006-06-07 US US11/448,965 patent/US20060280800A1/en not_active Abandoned
- 2006-06-08 AR ARP060102394A patent/AR057060A1/es not_active Application Discontinuation
-
2011
- 2011-11-09 US US13/292,405 patent/US8664208B2/en not_active Expired - Fee Related
-
2014
- 2014-01-16 US US14/156,863 patent/US20140194398A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008543758A5 (enExample) | ||
| JP7140355B2 (ja) | エステトロール成分を含有する口腔内崩壊性投与単位 | |
| TW576741B (en) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | |
| JP6813150B2 (ja) | エステトロールを含有する口腔内崩壊錠 | |
| JP6447931B2 (ja) | エステトロール成分を含有する口腔内崩壊固体単位剤形 | |
| JP5339903B2 (ja) | エチニルエストラジオールを含むタナプロゲット組成物 | |
| JP2015110604A (ja) | Ｈｒｔ製剤 | |
| JP2016540021A5 (enExample) | ||
| AU2008315319A1 (en) | Antiemetic-oral contraceptive combination | |
| MD3310345T2 (ro) | Comprimată orodispersabilă ce conține estetrol | |
| ES2340610T3 (es) | Composiciones de tanaproget micronizado y procedimientos de preparacion de las mismas. | |
| TW201247240A (en) | Rapid dissolve tablet compositions for vaginal administration | |
| JP2005526083A (ja) | プロゲステロンの経口薬物送達システム | |
| EP1990044A1 (en) | Mifepristone pharmaceutical compositions and their methods of preparation | |
| JP2013533881A (ja) | バノキセリンを含有する医薬組成物 | |
| JP5054863B2 (ja) | 潰瘍性大腸炎治療剤 | |
| ES2590914T3 (es) | Preparación hormonal que contiene una combinación de etinilestradiol y acetato de clormadinona | |
| US5478571A (en) | Process for the preparation of substantially alcohol free pharmaceutical compositions | |
| ES2565688T3 (es) | Método anticonceptivo a base de un progestágeno y un estrógeno | |
| EP3164134A1 (en) | Method for providing regular contraception | |
| CN100348180C (zh) | 盐酸曲马多口腔崩解片剂及其制备方法 | |
| MX2007011704A (es) | Forma de dosificacion oral solida de valopi citabina (val-mcyd) y metodo para su preparacion. | |
| AU2005247101B2 (en) | Use of a combination of ethinyl estradiol and chlormadinone acetate for the production of a medicament | |
| EP2863900B1 (en) | Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process | |
| WO2023152658A1 (en) | Slow release drospirenone tablet composition |